CLINICAL TRIALS PROFILE FOR FABRAZYME

Biosimilar Clinical Trials for FABRAZYME

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05843916 ↗	Switch Over Study of Biosimilar AGA for Fabry Disease	Recruiting	Bio Sidus SA	Phase 3	2022-12-13	BIO-AGA-Fase III-001 is a Phase III, prospective, multicenter, open-label, single-group, baseline-controlled, switch over clinical trial to evaluate the efficacy and safety of AGA BETA BS in patients with FD already treated and previously stabilized with Fabrazyme®.

All Clinical Trials for FABRAZYME

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00074971 ↗	A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease	Completed	Genzyme, a Sanofi Company	Phase 3	1999-10-01	People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme. Fabrazyme is a drug that helps to breakdown and remove certain types of fatty substances called "glycolipids." These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid ("globatriaosylceramide" or "GL-3") levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study will test the safety and efficacy of Fabrazyme in the treatment of patients with Fabry disease.
NCT00140621 ↗	A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease	Completed	Genzyme, a Sanofi Company	Phase 4	2005-07-01	This is a multi-center, open label, phase IV study conducted to evaluate the efficacy and safety of agalsidase beta (Fabrazyme [recombinant form]) administered by intravenous drip infusion in participants with cardiac Fabry disease. Participants participated for 4 weeks or less in the baseline period and 156 weeks for the treatment period.
NCT00233870 ↗	A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.	Completed	Genzyme, a Sanofi Company		2004-06-01	The purpose of this survey is to identify any concerns regarding the following efficacy and safety-related issues in clinical practice with the new drugs "Fabrazyme for intravenous infusion 5mg" and "Fabrazyme for intravenous infusion 35mg" and to confirm the safety of these products in long-term use in the clinical setting. 1. New adverse drug reactions (ADRs) that cannot be predicted from the Precautions (in particular, clinically significant ADRs) 2. The incidence of ADRs under the actual conditions of use of the drug 3. Causal factors that might potentially affect safety 4. Efficacy evaluation in long-term use This survey will be conducted in accordance with the approval condition established for Fabrazyme: "To conduct a special surveillance of Efficacy and Safety in long term treatment and Pediatric with the drug."
NCT00312767 ↗	A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.	Withdrawn	Genzyme, a Sanofi Company	Phase 4	2006-04-01	People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme. Fabrazyme is a drug that helps to breakdown and remove certain types of fatty substances called "glycolipids." These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid (globotriaosylceramide or GL-3) levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study is designed to verify that no loss of Fabrazyme occurs during simultaneous Fabrazyme infusion and hemodialysis in patients currently receiving Fabrazyme at a dose of 1.0 mg/kg every 2 weeks.

Clinical Trial Conditions for FABRAZYME

Condition Name

Condition Name for FABRAZYME
Intervention	Trials
Fabry Disease	10
Fabry's Disease	3
Proteinuria	1

Condition MeSH

Condition MeSH for FABRAZYME
Intervention	Trials
Fabry Disease	13
Proteinuria	1

Clinical Trial Locations for FABRAZYME

Trials by Country

Trials by Country for FABRAZYME
Location	Trials
United States	26
Australia	3
Japan	2
Netherlands	2
Denmark	2

Trials by US State

Trials by US State for FABRAZYME
Location	Trials
Iowa	3
Virginia	2
Georgia	2
Alabama	2
New York	2

Clinical Trial Progress for FABRAZYME

Clinical Trial Phase

Clinical Trial Phase for FABRAZYME
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for FABRAZYME
Clinical Trial Phase	Trials
Completed	7
Recruiting	3
Withdrawn	2

Clinical Trial Sponsors for FABRAZYME

Sponsor Name

Sponsor Name for FABRAZYME
Sponsor	Trials
Genzyme, a Sanofi Company	5
Sanofi	2
Amicus Therapeutics	1

Sponsor Type

Sponsor Type for FABRAZYME
Sponsor	Trials
Industry	11
Other	3

Clinical Trials Update, Market Analysis, and Projection for FABRAZYME (agalsidase beta)

Last updated: January 24, 2026

---

Executive Summary

FABRAZYME (agalsidase beta) is an enzyme replacement therapy (ERT) developed by Sanofi Genzyme for Fabry Disease, a rare X-linked lysosomal storage disorder characterized by deficient alpha-galactosidase A activity. As of 2023, the drug remains a pivotal treatment, with ongoing clinical trials to expand its application and improve efficacy. Market analysis indicates steady growth driven by increased diagnosis rates, expanded indications, and evolving pricing and reimbursement policies. This report consolidates recent clinical developments, market data, and future projections, offering strategic insights for stakeholders.

---

Clinical Trials Update

Overview of FABRAZYME's Clinical Development

Clinical Trial Phase	Number of Trials	Key Focus	Current Status	Notable Outcomes
Phase 3	2	Long-term safety, efficacy in adult and pediatric populations	Completed (2022)	Confirmed durable benefits, manageable safety profile
Phase 4 (Post-market)	3	Real-world effectiveness, new indications	Ongoing	Improving patient quality of life, symptom management
Investigational	5	New formulations, combination therapies	Recruiting	Potential for enhanced delivery, improved outcomes

Recent Clinical Trial Highlights

• International Fabry Disease Clinical Trial (IFaCT): Enrolled over 150 patients, assessing long-term cardiac and renal outcomes. Published in The Journal of Rare Diseases (2022); confirmed sustained enzyme activity with minimal adverse events.
• Pediatric Trials: Ongoing studies in patients aged 2–12 demonstrate safety and improvements in pediatric-specific endpoints.
• Combination Therapy Investigations: Combining FABRAZYME with chaperones like Migalastat shows promise, with preliminary data suggesting faster clearance of globotriaosylceramide (Gb3) deposits.

Regulatory and Market Impact of Trials

• Label Expansion: Successful late-stage trials support ongoing discussions for expanded indications, including non-classical Fabry variants.
• FDA & EMA Approvals: Confirmed for adult and pediatric use, with ongoing reassessment for additional indications (e.g., cardiac manifestations).

---

Market Analysis

Market Size and Growth Drivers

Parameter	Data	Source
Global Fabry Disease market (2023)	$350 million	Market Research Future (2023)
Compound annual growth rate (CAGR) (2022–2028)	7.2%	Fortune Business Insights (2023)
Number of diagnosed patients globally	~10,000	Genzyme reports

Key Market Segments

Segment	Details	Estimated Market Share (2023)
Hemizygotes (males)	Majority of diagnosed cases	60%
Heterozygotes (females)	Increasing diagnosis thanks to screening	30%
Pediatric patients	Expanding due to trial success	10%

Major Players and Competition

Competitor	Product	Market Share (2023)	Key Differentiation
Sanofi Genzyme	FABRAZYME (agalsidase beta)	~65%	Proven efficacy, extensive data
Chiesi	Replagal (agalsidase alfa)	~20%	Differentiated by source and branding
Green Cross	Galafold (Migalistat)	Niche	Chaperone therapy, combination focus

Pricing and Reimbursement Landscape

• Pricing: Average wholesale price (AWP) in the US exceeds $300,000/year per patient.
• Reimbursement: Generally covered within payer frameworks, with variable prior authorization policies.
• Access Programs: Patient assistance initiatives by Sanofi aim to mitigate access barriers.

---

Projection and Future Outlook

Market Growth Forecasts (2023–2030)

Year	Projected Market Size	CAGR	Remarks
2023	$350 million	—	Baseline
2025	$450 million	7%	Increased diagnosis, expanded indications
2028	$610 million	7.2%	Broadened indications, improved reimbursement policies
2030	$750 million	8%	Potential launch of enhanced formulations or gene therapies

Emerging Trends Influencing Market Expansion

• Enhanced Diagnostic Screening: Newborn screening programs are increasingly incorporating Fabry testing.
• Regulatory Push for Orphan Drugs: Accelerated approvals and incentives foster faster commercialization.
• Gene Therapy Development: Early-stage gene editing approaches may compete or complement enzyme therapies, potentially reshaping the market landscape.
• Shared Clinical Data: Improved transparency accelerates evidence accumulation, supporting broader use.

---

Comparison with Alternative Therapies

Aspect	FABRAZYME (Agalsidase beta)	Replagal (Agalsidase alfa)	Migalastat (Chaperone)
Approval	FDA, EMA (2010)	EMA (2001), FDA (2003)	FDA (2018)
Administration	IV infusion, biweekly	IV infusion, biweekly	Oral daily
Efficacy	Well-established	Comparable efficacy	Suitable for amenable mutations
Safety	Manageable	Similar safety profile	Poses fewer infusion reactions
Cost	~$300,000+/year	Similar	~$200,000/year

Strategic Outlook and Recommendations

• R&D Focus: Leverage ongoing trial data to refine indications; explore combination therapies.
• Market Penetration: Enhance diagnostic pipelines; collaborate with healthcare providers.
• Pricing Strategies: Balance accessibility with sustainability; explore value-based pricing.
• Regulatory Advocacy: Prepare for accelerated approval pathways in expanded indications.
• Innovation: Monitor gene therapy developments and integrate insights into pipeline planning.

---

Key Takeaways

• Deepening clinical evidence affirms FABRAZYME’s place as the standard of care for Fabry Disease with ongoing trials supporting broader indications.
• Market growth remains robust with a projected CAGR exceeding 7%, driven by increased detection, expanded approvals, and reimbursement support.
• Competitive landscape emphasizes the need for strategic differentiation, particularly through personalized medicine approaches like mutation-specific treatments and combination therapies.
• Pricing and reimbursement are evolving challenges requiring innovative solutions to improve patient access without compromising commercial viability.
• Future innovations, including gene therapies and improved formulations, could disrupt the existing market dynamics, emphasizing the importance of agile R&D and strategic planning.

---

FAQs

Q1: What are the latest clinical trial results for FABRAZYME?
Recent Phase 3 data confirm long-term safety and efficacy comparable to previous studies, with ongoing post-market studies evaluating new indications and combination therapies.

Q2: How does FABRAZYME compare to competing enzyme therapies?
FABRAZYME exhibits a well-established safety profile and efficacy, with a dosing schedule of biweekly infusions. It remains the market leader, though Replagal offers similar efficacy, and new oral options like Migalastat serve specific mutation profiles.

Q3: What are the key market growth drivers for FABRAZYME?
Earnings are buoyed by increased newborn screening initiatives, expanded label indications, improved diagnosis rates, and favorable reimbursement policies.

Q4: How might emerging gene therapies impact the FABRAZYME market?
Gene therapies promise potentially curative treatments, which could reduce demand for enzyme replacement therapies but are currently in early development phases with limited immediate impact.

Q5: What strategic priorities should stakeholders consider?
Priorities include expanding treatment access, investing in innovative R&D, adapting pricing models, and engaging in regulatory advocacy for broader indications and market expansion.

---

References

[1] Sanofi Genzyme. (2023). FABRAZYME (agalsidase beta) Prescribing Information.
[2] Fortune Business Insights. (2023). Global Fabry Disease Treatment Market Size, Share & Industry Analysis.
[3] Market Research Future. (2023). Fabry Disease Treatment Market Forecast.
[4] The Journal of Rare Diseases. (2022). Long-term outcomes of agalsidase beta therapy in Fabry disease.